Thu, Nov 21, 2024
[Archive]
Volume 32, Issue 152 (May & June 2024)
J Adv Med Biomed Res 2024, 32(152): 168-173 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shabani J, Hemmati M, Sedighi M. The Effect of Intermittent Oral Anticonvulsant Levetiracetam in Prevention of Recurrence of Febrile Seizure in Children: A Randomized Clinical Trial Study. J Adv Med Biomed Res 2024; 32 (152) :168-173
URL: http://journal.zums.ac.ir/article-1-7360-en.html
URL: http://journal.zums.ac.ir/article-1-7360-en.html
1- Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Kermanshah University of Medical Sciences, Kermanshah, Iran ,sedighimostafa2000@gmail.com
2- Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract: (177 Views)
Background & Objective: Febrile seizure (FS) is the most common childhood seizure disorder that occurs in 3-4% of children .The aim of this study was to determine the effect of intermittent oral anticonvulsant Levetiracetam in prevention of the recurrence of febrile seizure (FS) in children.
Materials & Methods: This a randomized clinical trial study was conducted on 108 children with FS referred to the pediatric department of Mohammad Kermanshahi Hospital in Kermanshah in 2020. Then, eligible patients were divided into intervention (Levetiracetam; n= 72) and control (Acetaminophen; n= 36) groups using balanced block randomization. The intervention group received a dose of 30-60 mg/kg Levetiracetam during the febrile illness for prophylaxis for 9 months. In contrast, in the control group, only acetaminophen was prescribed just to reduce fever. Finally, the number of FS recurrences were studied in two groups. The data were analyzed using SPSS 26.
Results: The mean (±S.D) age were 2.37 (±1.01) vs. 2.30 (±0.95) years in the intervention and control groups; respectively. The number (%) of boys in the two groups under study was 39 (54.1) and 19 (52.7), respectively. The mean time to first seizure recurrence after the intervention was significantly longer in the intervention group (5.70 ± 0.82 months) than in the control group (2.32 ± 0.75 months) (P-Value<0.05). Also, the mean number of recurrences of FS in the intervention group (2.25 ± 0.80) was significantly lower than the control group (4.13 ± 0.79) (P-Value<0.05).
Conclusion: The administration of oral anticonvulsant Levetiracetam may be effective in the reduction of the recurrences of FS, however, detailed studies in this field is recommended.
Materials & Methods: This a randomized clinical trial study was conducted on 108 children with FS referred to the pediatric department of Mohammad Kermanshahi Hospital in Kermanshah in 2020. Then, eligible patients were divided into intervention (Levetiracetam; n= 72) and control (Acetaminophen; n= 36) groups using balanced block randomization. The intervention group received a dose of 30-60 mg/kg Levetiracetam during the febrile illness for prophylaxis for 9 months. In contrast, in the control group, only acetaminophen was prescribed just to reduce fever. Finally, the number of FS recurrences were studied in two groups. The data were analyzed using SPSS 26.
Results: The mean (±S.D) age were 2.37 (±1.01) vs. 2.30 (±0.95) years in the intervention and control groups; respectively. The number (%) of boys in the two groups under study was 39 (54.1) and 19 (52.7), respectively. The mean time to first seizure recurrence after the intervention was significantly longer in the intervention group (5.70 ± 0.82 months) than in the control group (2.32 ± 0.75 months) (P-Value<0.05). Also, the mean number of recurrences of FS in the intervention group (2.25 ± 0.80) was significantly lower than the control group (4.13 ± 0.79) (P-Value<0.05).
Conclusion: The administration of oral anticonvulsant Levetiracetam may be effective in the reduction of the recurrences of FS, however, detailed studies in this field is recommended.
Type of Study: Clinical Trials |
Subject:
Clinical medicine
Received: 2023/09/29 | Accepted: 2024/10/2 | Published: 2024/06/21
Received: 2023/09/29 | Accepted: 2024/10/2 | Published: 2024/06/21
References
1. Kavanagh FA, Heaton PA, Cannon A, Paul SP. Recognition and management of febrile convulsions in children. Br J Nurs. 2018;27(20):1156-62. [DOI:10.12968/bjon.2018.27.20.1156]
2. Smith DK, Sadler KP, Benedum M. Febrile seizures: risks, evaluation, and prognosis. Am Family Physic. 2019;99(7):445-50.
3. Eilbert W, Chan C. Febrile seizures: A review. J Am College Emerg Physic Open. 2022;3(4):e12769. [DOI:10.1002/emp2.12769]
4. Whelan H, Harmelink M, Chou E, Sallowm D, Khan N, Patil R, et al. Complex febrile seizures-A systematic review. Dis Mon. 2017;63(1):5-23. [DOI:10.1016/j.disamonth.2016.12.001]
5. Kumar N, Midha T, Rao YK. Risk factors of recurrence of febrile seizures in children in a tertiary care hospital in Kanpur: A one year follow up study. Ann Indian Acad Neurol. 2019;22(1):31. [DOI:10.4103/aian.AIAN_472_17]
6. Minardi C, Minacapelli R, Valastro P, Vasile F, Pitino S, Pavone P, et al. Epilepsy in children: from diagnosis to treatment with focus on emergency. J Clin Med. 2019;8(1):39. [DOI:10.3390/jcm8010039]
7. Sawires R, Buttery J, Fahey M. A review of febrile seizures: recent advances in understanding of febrile seizure pathophysiology and commonly implicated viral triggers. Front Pediatr. 2022;9:801321. [DOI:10.3389/fped.2021.801321]
8. Gontko-Romanowska K, Żaba Z, Panieński P, Steinborn B, Szemień M, Łukasik-Głębocka M, et al. The assessment of laboratory parameters in children with fever and febrile seizures. Brain Behav. 2017;7(7):e00720. [DOI:10.1002/brb3.720]
9. Pavlidou E, Tzitiridou M, Panteliadis C. Effectiveness of intermittent diazepam prophylaxis in febrile seizures: long-term prospective controlled study. J Child Neurol. 2006;21(12):1036-40. [DOI:10.1177/7010.2006.00221]
10. Gavgani LF, Laghousi D, Sarbakhsh P, Jahangiri L, Vahed N, Hajebrahimi S. Comparing the effect of intermittent diazepam and continuous phenobarbital in preventing recurrent febrile seizures among children under 6 years old: A systematic review and meta-analysis. J Isfahan Univ Med Sci. 2023;28. [DOI:10.4103/jrms.jrms_1114_21]
11. Khosroshahi N, Faramarzi F, Salamati P, Haghighi SMO, Kamrani K. Diazepam versus clobazam for intermittent prophylaxis of febrile seizures. Indian J Pediatr. 2011;78:38-40. [DOI:10.1007/s12098-010-0220-0]
12. Pizza V, Busillo V, Agresta A, Bisogno A, Capasso A. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem. 2011;11(1):31-4. [DOI:10.2174/187152411794961086]
13. Mruk AL, Garlitz KL, Leung NR. Levetiracetam in neonatal seizures: a review. J Pediatr Pharmacol Therapeut. 2015;20(2):76-89. [DOI:10.5863/1551-6776-20.2.76]
14. Hu LY, Zou LP, Zhong JM, Gao L, Zhao JB, Xiao N, et al. Febrile seizure recurrence reduced by intermittent oral levetiracetam. Ann Clin Translat Neurol. 2014;1(3):171-9. [DOI:10.1002/acn3.34]
15. Hu LY, Shi XY, Li H, Zhang MN, Ma SF, Zou LP. Intermittent oral levetiracetam reduced recurrence of febrile seizure accompanied with epileptiform discharge: a pilot study. Italian J Pediatr. 2018;44:1-7. [DOI:10.1186/s13052-018-0507-8]
16. Chaudhary N, Narayana R, Chaudhary S. Reduction of febrile seizure recurrence comparative efficacy of intermittent oral levetiracetam vs clobazam.Am Acad Neurol. 2016; (P3. 239) [DOI:10.1212/WNL.86.16_supplement.P3.239]
17. Farzaneh Bajestani S , Pirzadeh Z, Farshadmoghadam H. Comparison of the effect of oral levetiracetam solution and intermittent oral diazepam tablets in reducing the recurrence of febrile seizures in children 6-60 months. Pakistan J Med Health Sci. 2021;15(4).
18. Offringa M, Newton R, Nevitt SJ, Vraka K. Prophylactic drug management for febrile seizures in children. Coch Database System Rev. 2021(6). [DOI:10.1002/14651858.CD003031.pub4]
19. Xu JC, Shen J, Shao WZ, Tang LJ, Sun YZ, Zhai XF, et al. The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis. Brain Injury. 2016;30(9):1054-61. [DOI:10.3109/02699052.2016.1170882]
20. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4(3):507-23. [DOI:10.2147/NDT.S2937]
21. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceed Nat Acad Sci. 2004;101(26):9861-6. [DOI:10.1073/pnas.0308208101]
22. Vogl C, Mochida S, Wolff C, Whalley BJ, Stephens GJ. The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Molec Pharmacol. 2012;82(2):199-208. [DOI:10.1124/mol.111.076687]
23. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006;69(3):273-94. [DOI:10.1016/j.eplepsyres.2006.02.004]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
